The War on Drugs vs. the Psychedelic Renaissance: What We’ve Learned, What We’ve Lost

Olga Chernoloz blog banner ()

For decades, the word “psychedelic” was politically toxic, scientifically suspect, and legally taboo. But today, society is revisiting that legacy with fresh eyes. The war on drugs, which once buried promising research and stigmatized ancient healing traditions, is now being challenged by a psychedelic renaissance. In Psychedelics A to Z, Dr. Olga Chernoloz traces the roots of this dramatic shift—and what it cost us to get here.

Olga Chernoloz cover
Olga Chernoloz cover

The “W is for War on Drugs” chapter lays it bare: prohibition wasn’t built on science. It was built on politics, fear, and often, racial bias. From the early demonization of cannabis and peyote to the full criminalization of LSD, psilocybin, and MDMA, the crackdown treated sacred and therapeutic substances as threats to society. The real damage? Decades of lost research, ruined lives, and the silencing of indigenous and community-based healing.

Dr. Chernoloz highlights the contradictions. Psychedelics like LSD were once seen as psychiatric tools. MDMA was praised by therapists for its ability to unlock emotional healing. But as these substances moved beyond clinics and into counterculture, they became symbols of rebellion—and convenient scapegoats for social unrest. The result: substances with low addiction potential and high therapeutic value were banned, often more harshly than far more harmful drugs like alcohol and tobacco.

But prohibition didn’t stop use. It pushed it underground. It fueled stigma, disrupted indigenous traditions, and made safe access impossible for millions. The war on drugs wasn’t just ineffective—it was destructive. And as Dr. Chernoloz makes clear, it’s a cautionary tale.

Now, we’re in the midst of a slow but undeniable renaissance. Clinical trials show that psychedelics, under the right conditions, can treat depression, PTSD, addiction, and end-of-life anxiety. The FDA has granted Breakthrough Therapy status to MDMA and psilocybin treatments. Universities, hospitals, and governments are taking psychedelics seriously again.

But this time, the tone is different. There’s a new awareness of the mistakes of the past—of how overenthusiasm and overreach once sparked backlash. Today’s researchers and advocates are moving more carefully, balancing excitement with evidence. They’re also working to ensure that traditional wisdom, ethical training, and equitable access don’t get lost in the wave of commercialization.

Still, the scars of the drug war remain. Dr. Chernoloz points out how legal reforms have often failed to include those most harmed by prohibition. Many indigenous communities still struggle for recognition of their ceremonial use. And in cities where psychedelics are decriminalized, access often favors the wealthy or well-connected.

So what have we learned? We’ve learned that prohibition is no substitute for education and harm reduction. That criminalization ruins lives more often than it protects them. And that healing—whether personal, cultural, or scientific—requires trust, not fear.

What have we lost? Time. Opportunities. Wisdom. And countless people who could have benefited from these tools, but didn’t get the chance.

What we have now is a second chance. And this time, we might just get it right.

 

Facebook
Twitter
LinkedIn
Pinterest